Astellas

Astellas inks biomarker deal to pinpoint Xtandi patients
BioPharma Dive
Sat, 02/4/17 - 09:59 am
Astellas
Xtandi
biomarkers
patients
tumor profiles
Astellas boosts pharma's rep with corporate branding push
Medical Marketing and Media
Tue, 11/1/16 - 09:51 am
Astellas
reputation
corporate branding
Astellas furthers oncology focus with Ganymed buy
BioPharma Dive
Fri, 10/28/16 - 05:48 pm
Astellas
oncology
Ganymed
M&A
IMAB362
gastroesophageal cancer
Congress just fired a shot against its next drug-pricing target, and its shares took a hit
Yahoo/Business Insider
Mon, 03/28/16 - 09:10 pm
US Congress
drug pricing
Medivation
Astellas
Xtandi
Astellas finally wraps up its $379M deal for Ocata
Fierce Biotech
Wed, 02/10/16 - 10:52 am
Astellas
Ocata Therapeutics
M&A
Astellas Extends Tender Offer to Acquire All Outstanding Shares of Ocata Therapeutics
Yahoo
Fri, 01/22/16 - 10:07 am
Astellas
Ocata Therapeutics
M&A
After shareholder revolt, Astellas says it needs more time for proposed buyout of Ocata
Bizjournals.com
Fri, 12/18/15 - 09:01 am
Astellas
Ocata Therapeutics
M&A
shareholders
Ocata investors scramble to nix Astellas' $379M buyout at the 11th hour
Fierce Biotech
Tue, 12/15/15 - 04:23 pm
Astellas
M&A
Ocata Therapeutics
Medivation's Xtandi sales force due for hiring, revamp as urology push falls flat
Fierce Pharma Marketing
Wed, 11/11/15 - 09:10 pm
Medivation
Xtandi
hirings
Astellas
Astellas to Acquire Ocata Therapeutics
Yahoo
Tue, 11/10/15 - 08:36 am
Astellas
Ocata Therapeutics
M&A
ophthalmology
4 Blockbuster Drugs Whose Sales Could Easily Double
Motley Fool
Mon, 10/26/15 - 08:46 am
Xtandi
Medivation
Astellas
Eliquis
Pfizer
Bristol-Myers Squibb
Revlimid
Celgene
Invokana
JNJ
District Court Rules for FDA in Battle Over the Scope of 3-Year Exclusivity in the Context of Dueling Tacrolimus NDAs
FDA Law Blog
Wed, 06/17/15 - 06:36 pm
FDA
exclusivity
Astellas
Veloxis
kidney transplants
Envarsus
Astellas, Medivation to amp up unbranded Xtandi marketing for pre-chemo use
Fierce Pharma Marketing
Wed, 06/17/15 - 10:24 am
Astellas
Medivation
Xtandi
drug marketing
prostate cancer
Astellas wagers $760M to launch an autoimmune biotech in Cambridge, MA
Fierce Biotech
Wed, 06/3/15 - 11:12 am
Astellas
autoimmune disease
Kanyos Bio
Anokion
Medivation's Xtandi sales fell short in Q1, but analysts say it's gaining on J&J's Zytiga
Fierce Pharma Marketing
Wed, 05/20/15 - 06:15 pm
Medivation
Xtandi
Astellas
JNJ
Zytiga
Medivation's Xtandi Beats Casodex In Cancer Trial
Investors.com
Fri, 04/3/15 - 08:38 am
Medivation
Xtandi
Casodex
Astellas
prostate cancer
11 promising drugs poised to be the next billion-dollar blockbusters
Yahoo/Business Insider
Sat, 03/28/15 - 10:26 am
Opdivo
Praluent
LCZ696
lumacaftor
Viekira Pak
evolocumab
Gardasil 9
brexpiprazole
Toujeo
Cosentyx
Bristol-Myers Squibb
Regeneron
Sanofi
Novartis
Pfizer
AbbVie
Amge
Astellas
Merck
Otsuka
Lundbeck
Vertex Pharmaceuticals
Why 2015 is the year of the biopharma blockbuster—with charts
BioPharma Dive
Tue, 03/24/15 - 10:29 am
biotech
Opdivo
Praluent
LCZ696
Ibrance
Viekira Pak
evolocumab
Gardasil 9
Bristol-Myers Squibb
Regeneron
Sanofi
Novartis
Pfizer
Vertex Pharmaceuticals
Merck
Amgen
AbbVie
Astellas
Astellas bags FDA approval for a new anti-infective
Fierce Biotech
Fri, 03/6/15 - 03:05 pm
Astellas
FDA
antifungals
Cresemba
Astellas bets on Immunomic's allergy vaccine in a $75M deal
Fierce Biotech
Fri, 01/30/15 - 08:03 am
Astellas
Immunomic
vaccines
LAMPs
allergies

Pages